Vaxcyte PCVX
NASDAQ PCVX
$56.66 -0.24 (-0.42%)
As of: Oct 1, 2026 · 10:46 AM EDT

Vaxcyte (PCVX) Non Operating Interest Expenses (2019 - 2022)

Updated

Vaxcyte (PCVX) posted Non Operating Interest Expenses of $2,000 for FY2022, down 71.4% from $7,000 in FY2021.

Analysis

Vaxcyte (PCVX) Non Operating Interest Expenses (2019 - 2022) Analysis & Trends

Since FY2018, Vaxcyte has reported Non Operating Interest Expenses for 5 years.

  • Annual Non Operating Interest Expenses shows a four-year compound annual growth rate of -59.6% (FY2018 to FY2022).
  • The FY2022 figure stands as the lowest annual Non Operating Interest Expenses in data going back to FY2018.
  • Business Quant data shows PCVX's Non Operating Interest Expenses at $7,000 in FY2021 (unchanged), $7,000 in FY2020 (-82.5%), $40,000 in FY2019 (-46.7%) and $75,000 in FY2018.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Interest Expenses (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn 281.00 Mn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn -
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn -
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn -462.00 Mn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn -435.00 Mn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn 673.00 Mn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn 247.00 Mn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn -
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn -
10 Vaxcyte 8.24 Bn 8.24 Bn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2022 2,000.00
Jun 30, 2021 7,000.00
Mar 31, 2020 7,000.00
Dec 31, 2019 7,000.00
Sep 30, 2019 9,000.00
Jun 30, 2019 11,000.00
API Access

Vaxcyte Non Operating Interest Expenses API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-operating-interest-expenses&ticker=PCVX&period=max&api_key=YOUR_API_KEY